The Use of the LanthaScreen TR-FRET CAR Coactivator Assay in the Characterization of Constitutive Androstane Receptor (CAR) Inverse Agonists
Jazyk angličtina Země Švýcarsko Médium electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
25905697
PubMed Central
PMC4431184
DOI
10.3390/s150409265
PII: s150409265
Knihovny.cz E-zdroje
- MeSH
- biotest metody MeSH
- isochinoliny farmakologie MeSH
- klotrimazol farmakologie MeSH
- konstitutivní androstanový receptor MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- oximy farmakologie MeSH
- receptory cytoplazmatické a nukleární agonisté antagonisté a inhibitory metabolismus MeSH
- thiazoly farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime MeSH Prohlížeč
- isochinoliny MeSH
- klotrimazol MeSH
- konstitutivní androstanový receptor MeSH
- oximy MeSH
- PK 11195 MeSH Prohlížeč
- receptory cytoplazmatické a nukleární MeSH
- thiazoly MeSH
The constitutive androstane receptor (CAR) is a critical nuclear receptor in the gene regulation of xenobiotic and endobiotic metabolism. The LanthaScreen(TM) TR-FRET CAR coactivator assay provides a simple and reliable method to analyze the affinity of a ligand to the human CAR ligand-binding domain (LBD) with no need to use cellular models. This in silico assay thus enables the study of direct CAR ligands and the ability to distinguish them from the indirect CAR activators that affect the receptor via the cell signaling-dependent phosphorylation of CAR in cells. For the current paper we characterized the pharmacodynamic interactions of three known CAR inverse agonists/antagonists-PK11195, clotrimazole and androstenol-with the prototype agonist CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3] thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) using the TR-FRET LanthaScreen(TM) assay. We have confirmed that all three compounds are inverse agonists of human CAR, with IC50 0.51, 0.005, and 0.35 μM, respectively. All the compounds also antagonize the CITCO-mediated activation of CAR, but only clotrimazole was capable to completely reverse the effect of CITCO in the tested concentrations. Thus this method allows identifying not only agonists, but also antagonists and inverse agonists for human CAR as well as to investigate the nature of the pharmacodynamic interactions of CAR ligands.
Zobrazit více v PubMed
Carazo Fernandez A., Smutny T., Hyrsova L., Berka K., Pavek P. Chrysin, baicalein and galangin are indirect activators of the human constitutive androstane receptor (CAR) Toxicol. Lett. 2015;233:68–77. doi: 10.1016/j.toxlet.2015.01.013. PubMed DOI
Chai X., Zeng S., Xie W. Nuclear receptors PXR and CAR: Implications for drug metabolism regulation, pharmacogenomics and beyond. Expert Opin. Drug Metab. Toxicol. 2013;9:253–266. doi: 10.1517/17425255.2013.754010. PubMed DOI
Jiang M., Xie W. Role of the constitutive androstane receptor in obesity and type 2 diabetes: A case study of the endobiotic function of a xenobiotic receptor. Drug Metab. Rev. 2013;45:156–163. doi: 10.3109/03602532.2012.743561. PubMed DOI
Wada T., Gao J., Xie W. PXR and CAR in energy metabolism. Trends Endocr. Metab. 2009;20:273–279. doi: 10.1016/j.tem.2009.03.003. PubMed DOI
Ingraham H.A., Redinbo M.R. Orphan nuclear receptors adopted by crystallography. Curr. Opin. Struct. Biol. 2005;15:708–715. doi: 10.1016/j.sbi.2005.10.009. PubMed DOI
Osabe M., Negishi M. Active ERK1/2 protein interacts with the phosphorylated nuclear constitutive active/androstane receptor (CAR; NR1I3), repressing dephosphorylation and sequestering CAR in the cytoplasm. J. Biol. Chem. 2011;286:35763–35769. doi: 10.1074/jbc.M111.284596. PubMed DOI PMC
Mutoh S., Sobhany M., Moore R., Perera L., Pedersen L., Sueyoshi T., Negishi M. Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling. Sci. Signal. 2013;6:ra31. doi: 10.1126/scisignal.2003705. PubMed DOI PMC
Yang H., Wang H. Signaling control of the constitutive androstane receptor (CAR) Protein Cell. 2014;5:113–123. doi: 10.1007/s13238-013-0013-0. PubMed DOI PMC
Maglich J.M., Parks D.J., Moore L.B., Collins J.L., Goodwin B., Billin A.N., Stoltz C.A., Kliewer S.A., Lambert M.H., Willson T.M., Moore J.T. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J. Biol. Chem. 2003;278:17277–17283. doi: 10.1074/jbc.M300138200. PubMed DOI
Moore L.B., Parks D.J., Jones S.A., Bledsoe R.K., Consler T.G., Stimmel J.B., Goodwin B., Liddle C., Blanchard S.G., Willson T.M., Collins J.L., Kliewer S.A. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 2000;275:15122–15127. doi: 10.1074/jbc.M001215200. PubMed DOI
Li L., Chen T., Stanton J.D., Sueyoshi T., Negishi M., Wang H. The peripheral benzodiazepine receptor ligand 1-(2-chlorophenyl-methylpropyl)-3-isoquinoline-carboxamide is a novel antagonist of human constitutive androstane receptor. Mol. Pharmacol. 2008;74:443–453. doi: 10.1124/mol.108.046656. PubMed DOI PMC
Forman B.M., Tzameli I., Choi H.S., Chen J., Simha D., Seol W., Evans R.M., Moore D.D. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature. 1998;395:612–615. doi: 10.1038/26996. PubMed DOI
LanthaScreen™ TR-FRET Constitutive Androstane Receptor Coactivator Assay Manual. Invitrogen Corporation; Carlsbad, CA, USA: 2007. Manufacturer’s_Manual, Invitrogen, Assay Pharmacology.
Kupcho K.R., Stafslien D.K., DeRosier T., Hallis T.M., Ozers M.S., Vogel K.W. Simultaneous monitoring of discrete binding events using dual-acceptor terbium-based LRET. J. Am. Chem. Soc. 2007;129:13372–13373. doi: 10.1021/ja074791h. PubMed DOI
Zhang J.H., Chung T.D., Oldenburg K.R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999;4:67–73. doi: 10.1177/108705719900400206. PubMed DOI
Kenakin T., Williams M. Defining and characterizing drug/compound function. Biochem. Pharmacol. 2014;87:40–63. doi: 10.1016/j.bcp.2013.07.033. PubMed DOI
Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., Stimmel J.B., Willson T.M., Zavacki A.M., Moore D.D., et al. Bile acids: Natural ligands for an orphan nuclear receptor. Science. 1999;284:1365–1368. doi: 10.1126/science.284.5418.1365. PubMed DOI
Collins J.L., Parks D.J. Constitutive Androstane Receptor. Patent WO 2001071361 A2. 2001